Plain-English translation of NCT04167969 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a new type of imaging tracer called PSMA-targeting nanoparticles can help surgeons find prostate cancer more accurately during surgery. You would receive an injection of this tracer before your scheduled prostate cancer surgery, then undergo imaging scans (PET/MRI) to see how the medication travels through your body and lights up cancer cells. The goal is to determine whether this medication makes surgery safer and more effective by helping doctors identify all cancerous tissue.
Standard surgery for prostate cancer can sometimes miss cancer cells that are hard to see with the naked eye or conventional imaging. This trial is exploring whether the medication can help surgeons visualize and remove cancer more completely, potentially improving outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You would receive an intravenous injection of the tracer up to 48 hours before your scheduled surgery. Before surgery, you would undergo PET/MRI imaging scans to see how the medication is distributed in your body. Blood and urine samples would be collected at a few time points to measure how the medication moves through your system. Then you would proceed with your standard surgical care as planned, potentially benefiting from improved visualization of cancer cells during the operation.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States